Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer

It is often challenging to diagnose newly emerged abnormal lung shadows during treatment with immune checkpoint inhibitors. We report an autopsy case of a patient who developed lipoid pneumonia after a single dose of pembrolizumab. Clinicians will bear in mind this rare but severe phenomenon in patients undergoing immune checkpoint inhibitor therapy. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

Diagnosing newly emerged abnormal lung shadows during treatment with immune checkpoint inhibitors can be challenging. Clinicians should be aware of this rare but severe phenomenon in patients undergoing immune checkpoint inhibitor therapy.